-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the introduction of targeted drugs into the treatment paradigm of chronic lymphocytic leukemia (CLL), the prognosis of patients has been significantly improved
With the introduction of targeted drugs into the treatment paradigm of chronic lymphocytic leukemia (CLL), the prognosis of patients has been significantly improved
In this analysis, 1303 patients with recorded CLL diagnoses between 2013 and 2018 were included
1303 patients with recorded CLL diagnoses from 2013 to 2018 were included
Although the previous comorbidities and ECOG status of patients in the treatment group and the untreated group were similar, the proportion of advanced patients with del (17p), unmutated IGHV and Binet was higher in the treatment group
But in the treatment group, the incidence of all SPM, especially hematology SPM, was higher than expected
In this analysis, they found that the incidence of SPM among treated CLL patients was 42% higher than that of the general population.
The incidence of SPM in treated CLL patients was 42% higher than that in the general population, mainly because the incidence of hematological SPM was higher than expected, while untreated CLL patients did not have an increased risk of SPM compared with the general population
Original source:
Original source:Fürstenau, M.
Fürstenau, M.
, Giza, A.
, Stumpf, T.
, Robrecht, S.
, Maurer, C.
, Linde, H.
, Jacobasch, L.
, Dörfel, S.
, Aldaoud, A.
, von Tresckow, J.
, Koenigsmann, M.
, Gaska, T.
, Kaiser, U.
, Harich, H.
-D.
, Fischer, K.
, Eichhorst, B.
, Hallek, M.
and Fink, A.
-M.
(2021), Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
Am J Hematol.
Accepted Author Manuscript.
https://doi.
org/10.
1002/ajh.
26363
Leave a message here